Do y’all advise to buy CKPT right now? There was some speculation here that the stock would rise quite a bit since their FDA approval.

$RIME: Has been on my radar since inking a deal with Carpool Karaoke.

In the past 2-3 months, they have announced a deal with BYD and Stingray, a restructuring of their Board and a $9.5M raise at $0.17.

They also have an Ai division focused on logistics and supply chain innovation that is gaining steam with large OEMs

I placed a 10k share purchase on Friday at $0.078. I’d love to hear your thoughts.

ChatGPT Summary:

RIME: Driving Innovation with New Investments, Partnerships, and AI Logistics

RIME is entering a transformative phase with fresh leadership, key investments, and dynamic partnerships that position it as a trailblazer in the logistics and technology sectors. A newly energized board, a strategic focus on AI-powered logistics, and a groundbreaking partnership with BYD highlight the company’s vision for innovation and growth.

A New Board to Steer a Bold Vision

RIME’s recent board restructuring has brought in seasoned leaders with deep expertise in technology, logistics, and strategic innovation. This team is set to drive the company’s future with a sharper focus on scaling operations and fostering partnerships that redefine industry standards. Their collective experience ensures that RIME is well-equipped to meet the challenges and opportunities ahead.

A Strategic Partnership with BYD

In an exciting collaboration, RIME has partnered with BYD. This partnership goes beyond logistics. A key focus is in-car entertainment, specifically karaoke systems, which BYD has been pioneering in its next-generation EVs.

RIME’s role in this partnership includes developing integrated solutions that merge logistics and entertainment, creating seamless user experiences for BYD vehicle owners. By blending advanced AI logistics capabilities with BYD’s in-car karaoke technology, RIME is exploring new ways to enhance connectivity, convenience, and customer satisfaction in the EV market.

This collaboration demonstrates RIME’s adaptability and commitment to diversifying its impact across industries, leveraging BYD’s innovation to break into the growing intersection of mobility and entertainment.

AI-Driven Logistics: Revolutionizing the Supply Chain

RIME continues to invest heavily in AI-driven logistics, a cornerstone of its growth strategy. Through its partnership with a leading AI logistics firm, RIME is delivering cutting-edge solutions that optimize supply chain operations for large-scale partners.

These innovations include:

•	Predictive Delivery: Leveraging AI to anticipate customer needs and streamline operations.
•	Autonomous Decision-Making: Using machine learning to allocate resources more efficiently.
•	Seamless Integration: Providing partners with scalable, adaptive systems tailored to their unique logistics challenges.

This focus on AI has already secured RIME several high-profile deals, cementing its status as a trusted leader in supply chain modernization.

Strategic Investment at $0.17

RIME’s recent investment round, priced at $0.17 per share, signals robust confidence in the company’s future. The capital raised will fuel growth across several key areas, including further AI innovation, global market expansion, and the development of next-gen technologies like its work with BYD.

For investors, this is an opportunity to partner with a company on the cutting edge of logistics, entertainment, and sustainable technology solutions.

Expanding Partnerships with Industry Leaders

RIME’s strategic focus on partnerships has resulted in deals with major global players, extending its reach into new markets. These alliances leverage RIME’s AI logistics capabilities and innovative approaches to redefine supply chain efficiency and customer engagement.

The Road Ahead

RIME’s bold moves—restructuring its board, investing in AI, and forming unique partnerships like its collaboration with BYD—position the company for sustained growth. By blending logistics innovation with emerging technologies like in-car karaoke, RIME is expanding its influence across industries.

As the company continues to secure deals with large-scale partners and explore new applications of its technology, RIME is proving itself as a leader in innovation and strategic growth.

For investors, partners, and customers, RIME’s journey offers a glimpse into the future of logistics, mobility, and beyond.

It has been confirmed that on December 20th Sidus Space will launch the LizzieSat-2 and LizzieSat-3 into space partnered with SpaceX. Click this link: https://en.m.wikipedia.org/wiki/List_of_spaceflight_launches_in_July%E2%80%93December_2024

Type Ctrl+F and type Sidus, click enter until you see the December 20th Launch. Here is a PR recently confirming it will be December https://dilution.news/1d2b781f71c2600d44a3b6db5310e052 now it is confirmed it will be December 20th (Friday this week)

CVKD Very interesting play here. Late stage biopharma play trading at a 18M market cap, $2B annual target market with FDA fast track designation and orphan drug status. Phase 3 collaboration with Abbott $ABT, a $200B dollar company.

Tecarfarin has been evaluated in 11 clinical trials in over 1,003 subjects: 269 patients were treated for at least 6 months and 129 patients were treated for one year or more. In Phase 1, Phase 2, and Phase 2/3 clinical trials, tecarfarin has generally been well-tolerated in both healthy adult subjects and patients.

Significant unmet need & market opportunity for Tecarfarin ($2B annually) FDA granted them Fast Track designation and Orphan drug status, meaning they will have zero competition, 7 year market exclusivity upon FDA approval.

Buyouts for Cardiovascular Orphan Drugs are at premium prices:

•MyoKardia acquired by $BMY Bristol Myers Squibb for $13B

•FoldRX acquired by $PFE Pfizer for $400M

It's currently trading at $11 per share under the radar but getting found. Multiple analyst ratings last month, won’t be surprised to see additional ones. •$45 price target by Noble Financial •$32 price target by H.C. Wainwright

CVKD has a pretty low cash burn between $1M-2M per quarter and they currently have $11.3M cash based on their PR last month on November 7.

Also worth noting they have an insane board of directors for a 18M market cap company.

•Robert Lisicki joined the CVKD board last year. He’s also the current CEO of $ZURA and former CCO at Arena Pharmaceuticals which was ACQUIRED by $PFE Pfizer for $6.7B in 2022

•John Murphy also a director at CVKD. He served as a director at O Reilly $ORLY a 73 Billion dollar company and Apria Inc $APR which was ACQUIRED by $OMI Owens & Minor's for $1.6B

•Steven Zelenkofske also on the board of directors at CVKD. He held leadership positions at Boston Scientific Corporation $BSX a $132 billion dollar company, Novartis $NVS a $215 billion dollar company, AstraZeneca $AZN a $206 billion dollar company.

Overall it looks like an amazing play especially at the current levels it’s trading at. Hard to find a late stage biopharma play with such a low market cap. CVKD is also collaborating with Abbott for Phase 3 clinical trials which is huge.

•18M Market cap

•11.3M cash as of Nov 7 PR

•Zero debt

•Only 1.2M liabilities

•Collab w/ Abbott $ABT Phase 3 trials

•FDA Fast Track

•Orphan Drug status

•$2B annual market

•Significant unmet need & market opportunity

This company IPOd through a SPAC and in typical SPAC fashion was valued way too high and dumped hard after the merger. Once it finds its bottom I feel like it could be a solid play. Warrants have a 5 year expiration, if the stock gets back to the $10-$12 range you’re looking at a 10x on those.

Their processing plant will be completed in q2 2025 which is expected to process 36 million ft on helium annually. It’s hard to find any numbers right now but depending on the price of helium could be anywhere from 14-36 million annually.

Helium is used in AI chips so the demand will be growing and the price is expected to double by 2035.

https://finance.yahoo.com/news/oppenheimer-predicts-580-jump-2-110433507.html

Given denifanstat’s potential and SGMT’s $4.39 share price, Oppenheimer analyst Jay Olson believes now is the time to get in on the action.

“SGMT’s current market cap is ~$141M, which to us appears undervalued based on the promising MASH program with validation from large pharma, e.g. NVO and LLY’s clinical efforts to expand incretin approval beyond obesity into MASH and Boehringer Ingelheim’s recent $2B partnership with Suzhou Ribo Life Science Co. and Ribocure Pharmaceuticals to develop an siRNA-based MASH therapeutic… Our SOTP analysis values denifanstat at $18/share in F2–F3 MASH, $2/share in F4 MASH, $1/share in recurrent glioblastoma, $5/share in moderate-to-severe acne, and estimated cash by YE24 at $4/share,” Olson stated.

“While we see potential for denifanstat to attract market share through its differentiated efficacy and safety as a monotherapy, its potential as a combination therapy further strengthens our conviction surrounding its commercial success if approved,” the analyst added.

To this end, Olson rates SGMT an Outperform (i.e. Buy), along with a $30 price target. Should the target be met, a twelve-month gain in the shape of a substantial 583% could be in store.

Turning now to the rest of the Street, 5 Buys and no Holds or Sells have been published in the last three months. Therefore, SGMT boasts a Strong Buy consensus rating. With the average price target standing at $25.33, the upside potential comes in at ~477%. 

Taken from the Yahoo Finance article above.

I saw that Dev Shetty has just been appointed the CEO of Aberdeen, which piqued my interest.

Shetty has an excellent track record as a mining executive. He founded Fura Gems in 2017, which went on the find the largest ruby sold at auction ($ 34.5 million). He has been involved with several mining companies, including Prospect, which sold for over $ 500 million.

And he has bought 14.5 million shares from the market in December (about $ 600,000 worth) and been granted 5 million options. So he's incentivised.

Aberdeem has languished for years now, since it was founded in 2007. Having raised more than $ 50 million to invest in resource companies, it's only success was Brazil Potash which recently listed in the US, as I looked through their financial statements and MDA on Sedar.

The 621, 851 shares of GRO that Aberdeen owns (with a quoted price of US$ 9.70) means its market value is worth about C$ 8.5 million, which is about $ 1.5 million more than the market cap of of Aberdeen at about $ 7 million. This can be liquidated at a moment's notice as needed.

The website is outdated, there are no recent comments on the BBs, no one cares. Except.....

Why did Shetty not roll back, say, 10-1 and then invest? Because if you are going to bring in large instituitional investors, you need a sizeable public float so they can each get meaningful allocations of Aberdeen capital stock.

This tells me that a big deal(s) are afoot. So I bought 190,000 shares on Friday.

Shetty did not join to keep things steady as they are. I believe this stock will be re-rated.

As quantum computing continues to evolve, two companies are quietly making moves that could place them at the forefront of this revolution. Quantum eMotion Corp (QNC.V) and 01 Communique Laboratory Inc. (ONE.V) are innovating in quantum-safe encryption, a crucial technology as quantum computing threatens traditional cybersecurity.

With the global quantum computing market projected to reach $125 billion by 2030, these companies are in a prime position to benefit as demand for secure, quantum-resistant encryption skyrockets.

Quantum eMotion Corp (QNC.V)

•	Market Cap: CAD 54.93M
•	Stock Price: CAD 0.365
•	Shares Outstanding: ~150.5M
•	Insider Ownership: ~4.25%
•	Short Interest: Low, not significant

What They Do: Quantum eMotion is advancing quantum-safe encryption through its Quantum Random Number Generator (QRNG). This technology is essential for securing data in the face of quantum computing’s disruptive potential. Their QRNG technology is used across industries like IoT, blockchain, and financial services, ensuring the safety of digital transactions and communications.

01 Communique Laboratory Inc (ONE.V)

•	Market Cap: CAD 30.84M
•	Stock Price: CAD 0.32
•	Shares Outstanding: ~96.36M
•	Insider Ownership: ~12.91%
•	Short Interest: 0.14%

What They Do: 01 Communique focuses on post-quantum cryptography with their flagship product, IronCAP™, designed to protect sensitive data from quantum computing attacks. IronCAP™ offers quantum-safe encryption, ensuring long-term protection for businesses and governments. They also provide remote access solutions that are gaining traction in blockchain and 5G sectors.

https://www.rekor.ai/post/rekor-systems-reports-third-quarter-2024-financial-results

The earnings release from Rekor Systems presents a mix of positive developments and challenges, making the overall sentiment a bit nuanced. Here’s an analysis:

Bullish Indicators

1. Revenue Growth: Gross revenue increased by 16% year-over-year, with recurring revenue also rising 14%. This reflects growth in its core business.

2. Market Expansion:

• Florida DOT approved Rekor Discover™, with deployments underway.

• Significant projects in New York, New Mexico, and Hawaii demonstrate geographic and market expansion.

3. Notable Recognition:

• Texas DOT highlighted Rekor’s technology as a future model.

• The CEO’s appointment to the ITS America Board boosts credibility.

4. Partnerships and Innovations:

• Partnership with NVIDIA for generative AI applications indicates cutting-edge technology adoption.

• Collaboration with Goldwings expands its footprint in Hawaii.

5. Cost Optimization: The company is targeting a $15 million reduction in annual expenses, aiming to reach positive cash flow in 2025.

Bearish Indicators

1. Operational Losses: Losses from operations increased due to higher costs, including depreciation and expenses from the ATD acquisition.

2. Margins Pressure: Adjusted gross margins declined, likely due to a mix of lower-margin hardware sales and increased costs.

3. Performance Obligation Decline: A decrease in performance obligations from $26.4 million to $23.6 million indicates a potential slowdown in future revenue streams.

4. Government Procurement Delays: Variability in servicing government contracts was cited as a challenge, causing delays in revenue realization.

Neutral Observations

• The elimination of the $20 million advance option may signal confidence but also limits access to capital.

• EBITDA and Adjusted EBITDA details were not fully provided but highlight efforts to manage operational challenges.

Conclusion

While Rekor is showing promising growth and market recognition, ongoing losses, margin pressures, and reliance on unpredictable government contracts temper the bullish narrative. The outlook hinges on successful cost management and execution of key projects.

Net Sentiment: Cautiously bullish, but watch for sustained financial improvements.

Over the weekend, the nj drone story has headlined or front-paged on bloomberg, fox, nytimes, and wsj. It does not seem the story will necessarily disappear all that soon either. Here are some drone companies I think are compelling bets:

MOB -> This is my favorite of the lot. Its a pure play in controls systems, and integrate their systems with other major contractors. Only ~20m market cap and trades at ~4x sales. Good luck finding any small cap drone's trading at market caps that low or multiples that modest.

Why has this been under the radar? I think the drone frenzy a two weeks ago center on RCAT, UMACs headlines, and volume simply flooding a bunch of other squishy and highest si shitcos. Very much a smash and grab mentality. Folks were not drilling down for what could be the best fundamental winners over the long-terms.

I think think in light of those shitco popping off to new heights, this second time around folks will be digger a bit deeper, and be receptive to companies that seem to have less downside risk.

https://ir.mobilicom.com/wp-content/uploads/2024/09/240904_Mobilicom-Investor-Deck-Sept2024__V4-for-public-domain.pdf

ONDS -> My read is this was a struggling networks communication company that around two years ago decided to get into the drone game. I think they have serious products, but have been sub-scale and are just starting to see orders come in. I think this could very well be the juncture where the past two years of investment in drone tech starts to pay off into a viable business. They are unique on the non-otc exchanges for focusing on anti-drone tech. The iron drone looks pretty polished and you can see it in action here:

https://www.airoboticsdrones.com/iron-drone/

I think this could be a good fit for state law enforcement, which is realizing now that drones are fairly prevalent, and they have little way of dealing with them. This is also nice in the sense that is also went under the radar two weeks ago as well.

The CEO has been very active on X getting the word out about his tech in light of the NJ news.

DPRO -> They been in the game a long time, and seem to consistently burn a lot more cash they make. I don't expect this will change anytime soon. That said, it is a ~25m market cap drone pure-play and relative to peers has not moved all that much. This is my least favorite, but might be a way to diversify a bit for folks looking to go hard on the theme.

I have positions in all the companies.

Strategic Alignment

The acquisition of Riize LLC aligns seamlessly with IMD's strategic growth plans, expanding our market reach and portfolio of services.

About iMD Companies, Inc.

iMD Companies, Inc., (OTC: ICBU) is a Florida corporation, The company has re-positioned itself to focus on the health infusion technology markets. iMD's goal is to combine the expertise of our team members and subsidiaries in order to gain market share in the health acquisition and product development. iMD Companies, Inc. and our latest acquisition with Riize, LLC and the talented teams members will enable us to position ourselves in the Health product and technology development arena. We're excited to engage in this massive marketplace and look forward to fulfilling value to our shareholders and fulfilling our promises.

About Riize Health

Riize is revolutionizing the healthcare industry as a leading telemedicine and pharmacy services provider.

The company’s specialized focus on men’s and women’s sexual health and weight loss sets it apart from the competition, thanks to its innovative delivery system.

Riize offers a convenient and advanced online healthcare service that connects individuals with licensed healthcare providers.

Understanding the importance of personalized care, Riize provides a platform where patients can easily consult with healthcare professionals remotely. Through video or phone calls, individuals can discuss their symptoms, receive accurate diagnoses, and obtain personalized treatment plans tailored to their specific needs.

Riize is dedicated to breaking down barriers to healthcare access. With Riize, patients no longer have to endure long wait times or travel to a physical clinic. The user-friendly platform ensures that quality healthcare is just a few clicks away.

Join Riize in shaping the future of healthcare and experience the convenience and expertise offered. Health and well-being are priorities for Riize Health.

Recently in the news... "ICBU - iMD Companies and Its Subsidiary Riize Health Announce New Verticals With White Label and Licensing"

Riize Health Products

Enhances men’s sexual health with improved blood flow and endurance.Boosts libido and arousal, tailored for women’s wellness.Promotes thicker, healthier hair by supporting regrowth and reducing shedding.Accelerates metabolism and curbs appetite for effective, sustainable weight loss.

Riize Stip Explainer Video

This price is really low, it dropped almost 50% in a month. Maybe it’s tax loss selling, this dropped so much. Do you think cannabis stocks will bottom around here?

With the global push for cleaner energy and a more sustainable future, the electric vehicle (EV) industry is poised for rapid growth, driven by technological advances and government policies. Gogoro is gearing up for large-scale expansion in international markets like India. A key challenge to broader EV adoption has been the cost advantage of gas-powered vehicles in many regions. However, this balance is rapidly shifting as battery pack prices continue to decrease and governments increasingly promote sustainable transportation while implementing policies to phase out gas vehicles within the next 5-10 years. This shift presents an immense opportunity for Gogoro, which is now strategically refocusing its efforts on battery swapping as a core pillar of its growth strategy.

Record Decline in Lithium-Ion Battery Prices Marks a Turning Point for EVs

"Battery prices saw their biggest annual drop since 2017. Lithium-ion battery pack prices dropped 20% from 2023 to a record low of $115 per kilowatt-hour, according to analysis by research provider BloombergNEF (BNEF)."
Source: BloombergNEF

The trend is expected to continue, albeit at a slower pace.
"BNEF expects pack prices to decrease by $3/kWh in 2025, based on its near-term outlook. Looking ahead, continued investment in R&D, manufacturing process improvements, and capacity expansion across the supply chain will help improve battery technology and further reduce prices over the next decade."

While falling battery prices are a major driver for EV adoption, the industry is also looking to the future with cutting-edge innovations like solid-state batteries, which promise even greater efficiency and affordability.

Solid-State Batteries: A Glimpse Into the Future

New technologies are continually evolving, and the price per kilowatt-hour is likely to keep decreasing. Gogoro has already developed a prototype with solid-state batteries that are interoperable with its current vehicles. In the coming years, it may be the right time to integrate these advanced batteries into its existing battery-swapping network.
"In addition, next-generation technologies, such as silicon and lithium metal anodes, solid-state electrolytes, new cathode material, and new cell-manufacturing processes will play an important role in enabling further price reductions in the coming decade."

As battery technologies advance, so do opportunities for recycling and second-life applications. Lithium-ion batteries can be repurposed for energy storage solutions, reducing waste and creating new revenue streams. By recovering valuable materials like lithium, cobalt, and nickel, companies like Gogoro can also address supply chain sustainability while reducing costs. These advancements align with growing global efforts to make EV ecosystems more environmentally and economically sustainable.

India’s Push for Affordable EVs and Sustainability

As battery prices drop, EVs are becoming more affordable, particularly in cost-sensitive markets like India. The Indian government has ambitious goals for sustainable transportation.
"Gadkari explained that the cost of an EV battery, which was previously 150 USD per kWh, has now reduced to 110 USD per kWh. He added that when the price of batteries drops further to 100 USD per kWh, the cost of owning an electric vehicle will be comparable to that of diesel and petrol vehicles."
Source: MSN Autos

Transportation’s environmental impact is also driving policy change in India:
"40% of air pollution is caused by transport...I believe that the stubble burning issue we face in Delhi will be solved within 2 years: Union Minister u/nitin_gadkari tells u/navikakumar about the initiatives taken by the Centre to curb pollution."
Source: TimesNow

As India accelerates its EV transition, Gogoro’s battery-swapping model could play a crucial role in supporting urban commuters and delivery fleets, offering a faster and more flexible alternative to traditional charging stations.

Conclusion: A Sustainable Path Forward

The convergence of declining battery costs, innovative technologies, and supportive government policies is creating a perfect storm for EV adoption worldwide. Gogoro’s focus on battery swapping positions it as a critical enabler of this transition, particularly in emerging markets like India. As the EV landscape evolves, companies that can balance innovation with accessibility will shape the future of sustainable transportation.

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

Saw a big yikes post about ChatGPT in this sub, and thought I'd share my approach which is a bit more of a time investment but has worked well for me.

DISCLAIMER: I am not a financial advisor or analyst and you shouldn't listen to anything I say because I don't know anything about anything.

Tools I use: ChatGPT Plus Finviz

I started by having a conversation with ChatGPT o1 about how to read and interpret candlestick charts. I asked it to explain to me how they work, the different patterns and what they symbolize, and what astute swing traders look for. I asked what the best risk/reward ratios are, where to set a stop-loss, etc. I shared my personal trading style and risk tolerance. Even if you already know these things, it's important to do this so the model is "primed" to answer this next part effectively.

Then in that same chat I asked the model to put together complete and comprehensive instructions for a CustomGPT to perform an analysis of candlestick charts and swing trading outlook. I created a CustomGPT using those instructions.

Now, once or twice a week I visit the free screener on Finviz to filter on some data I prefer (like trading volume, price, etc) and then use the technical tab to filter on specific candlestick patterns that tend to be ideal for my trading style (yours will vary.)

With the filtered list, I screenshot the 30 day candlestick chart and feed it to my custom GPT 1 by 1 in the same chat. Once that's done, I ask the custom GPT in that chat to select the most favorable 3 of all the trades we talked about and put them in a table that displays Support, Resistance, Entry, Target, Stop Loss and risk/reward ratio. I personally don't enjoy anything with a reward ratio less than 4x but that's preference. Then I place my limit orders for the entries and let the market do whatever it's gonna do.

When/if my orders execute, I'm very disciplined about setting my stop-loss sell to minimize risk. Otherwise I look at it once a day and try to sell at target. If I'm wondering if I should adjust my plan (like a limit order that just won't execute or a target that's seeming too high/low) I go back to that chat with my CustomGPT and send it a new candlestick screenshot and ask for an updated analysis. It will use the context it had from before to speak to trend/interpretation.

Now, remember that I don't know anything about anything and you'd be a fool to listen to anything I say. I'm not a financial advisor or an AI engineer and you should assume I know nothing about either topic.

This is just an example of how to use an AI-assist in a less risky way. It won't make you rich, but I personally realize ~8% a week which is nice to watch compound. YMMV

It’s been coming up pretty good and was 1.8 in pre market like 2 days ago and bouncing between 1.05 and 1.5 for a bit. Just wanted to know if anyone else was in on it

Based on Q3 2024 financial results, annualised, this provides a revenue value of 355m and based on industry context for valuing companies, it is to be between 5-10x

Therefore, 5 x 335m is 1.775 billion USD

300m shares o/s gives a share value of 5.92

When looking at PE, with a PE ratio of 25x, this comes to 1.325 billion USD, giving a share value of 4.42

Estimated discounted cash flow value (DCF) is ranging between 5-6.50 per share

Therefore, just purely based on the current financials, the stock is heavily undervalued

The following news is a major milestone for Newron Pharmaceuticals! Evenamide is targeting a multi billion market of schizophrenia. EA just paid for 10% of a market share more than 100 Mio! Newron’s market cap is belo 200 Mio. Tenbagger ahead 🚀🚀🚀🚀

https://www.fiercebiotech.com/biotech/eisai-unit-hands-over-46m-japanese-rights-newrons-schizophrenia-add

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia rights to its add-on schizophrenia treatment.

When adding the upfront payment to potential development and commercialization milestones, the Italian biotech could be in line for a total of 117 million euros ($122.8 million) from Japan’s EA Pharma, along with tiered royalties up to a double-digit percentage of net sales.

In return, EA will get the license to develop, manufacture and commercialize evenamide in Japan and other designated Asian territories including Vietnam, Cambodia, Indonesia and the Philippines.

Evenamide, an innovative modulator of the excessive release of glutamate, was shown to improve both so-called positive and negative symptoms of schizophrenia when given as an add-on treatment to anti-psychotics like clozapine in a phase 2/3 study that read out in April.

At the time, Newron called the main endpoint results “highly statistically significant,” with patients on evenamide seeing a 10.2-point reduction on the Positive and Negative Syndrome Scale at Day 29, compared to 7.6 for the placebo group.

Newron's schizophrenia add-on improves symptoms, charging up case for phase 3 test Newron CEO Stefan Weber said in today’s release that the deal with EA would offer an “opportunity to advance evenamide through a phase 3 study and towards regulatory submission in Japan and other Asian territories by one of Japan’s leading pharmaceutical companies.”

“Newron will now focus on the initiation of our phase 3 one-year study in treatment-resistant schizophrenia and expect to start that study outside of the licensed territories in H1 2025,” Weber added. “We are also pursuing further development opportunities for evenamide in other territories.”

The schizophrenia space received a shot in the arm this year when Bristol Myers Squibb secured FDA approval for KarXT—now dubbed Cobenfy—marking the first new drug for the mental health condition in decades

Wheeler REIT ( https://www.whlr.us ) Seems to be under the radar because I cannot find much about it online. There are currently 0 shares to short. They recently did a Reverse Split. WHLR has experienced significant spikes the last few trading days and I can't find recent news of why but they reported 25 million in revenue ( their market cap is 6.2 million ! ) in November, from google:

Wheeler Real Estate Investment Trust, Inc. (WHLR) reported $25.2 million in revenue for the nine months ending September 30, 2022. For the third quarter of that year, WHLR reported $24.66 million in sales and $24.79 million in revenue. Here are some other recent financial highlights for WHLR:

• Revenue growth: WHLR has seen strong revenue growth over the past few years, with a three-year growth rate of 19.66% and a five-year rate of 10.26%. 
• Profitability: WHLR's financial statements show a 50.5% EBIT margin and an 83% gross margin, but a -3.6% pre-tax profit margin. 
• Operating cash flow: WHLR reported a healthy net operating cash flow of $7.88 million. 
• Working capital: WHLR reported changes in working capital of $2.05 million

My position is 1000 shares at $4.71 and will exit quickly if it does squeeze above the $6 dollar range other wise I will hold, Book value is $144.

I followed this stock for half a year, then I lost track and suddenly the stock skyrocketed.

Is this the quantum computing hype?

NRX Pharmaceuticals Inc (NRXP) seems like a stock that has quite a potential.

- Zero revenue for most of 2024 but projects $50 million in 2025 due to anticipated product launches and clinic acquisitions​. So it is projected to actually start generating revenue next year. Market cap 15 million, but estimated to generate 50 million $ in 2025.
- Has completed key FDA stability requirements for NRX-100/NRX-101 (ketamine treatment for $uicidal treatment resistant bipolar depression) , moving closer to filing a New Drug Application (NDA).
- Has secured 30 million $ in funding
- Has just appointed new CFO (Michael Abram) to guide its next growth phase​
- Analysts rate it as strong buy with astronomical price targets (low of $19 to a high of $47) compared to the current price of 1,20$.

Nobody seems to be talking about this stock. Is there some dirt to be uncovered why NRXP would be a bad play? It has burned a lot of people (−75,95 % YTD) but the future looks bright?

Graphene (not to be confused with graphite) is another form of carbon. Most of us are familiar with the two forms, graphite and diamond and that they have vastly different properties; graphene is no exception and has some remarkable properties, which can beuseful for batteries and as an additive to enhance plastics and cement.

Hydrograph clean power has the patent for a scalable method of making graphene, they have proved their technology, this isn't comparable to the google hyped quantum computer dream which maybe 20 years away from commercialisation. Graphene is being commercialised now.

Financing: they have finalised a recent private offering. Watch this:

https://www.youtube.com/watch?v=sPrhrmqzP1M&t=917s

an update of their collaborations can be found here

https://www.youtube.com/watch?v=mngzEQV6m5s

It''s a lot of information, but I have made my mind up on this company. I own 10000 shares, at the moment 1 share can be bought for 0.175 CAD.

This is a pre-revenue company and is inherently risky.

TLDR; OTC Has alot of potential and you should start trading it, look at $HMBL For example.

Hey, Most of you don't know me here, My name is Sean Twizer and I am a 7 figure OTC Trader.

in the past two weeks I have made 40k already solely from the OTC.

I can't add an image to show my gains but just check these: $CAFI $HMBL $RDAR

I just wanted to make more people aware of the fact that you can actually make a killing in the OTC and answer questions, not here to sell anything just want more people in this market so we can actually see some f crazy runs.

Have a great weekend :)

I open up a bunch of these posts, look at the stock recommendations, and then go look up the ticker only to see that the stock already ran up.

I’m not trying to buy high and sell low, why would I even think to buy a stock that already ran up?

KULR Technology Group $KULR has had a great month from a low of $0.31 to its Friday closing price of $1.18. The provider of advanced thermal management solutions for batteries, a designer in the small nuclear reactor industry,and in the AI sector recently reported record revenues (although marginal) and has won a contract with the US Navy, an undisclosed missile program and with Nvidia $NVDA. https://markets.businessinsider.com/news/stocks/kulr-xero-vibe-solution-launches-on-nvidia-jetson-edge-ai-platform-1034118908As is often the case in the lifespan of a small company, the beginnings of winning contracts with government departments and new industry leaders are a prelude for discovery by investors. With larger contracts from well known companies like Nvidia comes more investor interest. But there are always doubters (shorters). KULR has a short interest of 15.51 million shares (as of November 30)  a 71.19% increase in short interest from the previous month. But there are always doubters (shorters). Worth watching for news (and a very real potential for a short squeeze)

Red Cat Holdings $RCAT ($8.23) is reporting earnings on Monday with an Earnings Call at 4:30 PM Eastern. RCAT closed strong on Friday on high volume and is up in the After Hours. https://finance.yahoo.com/news/red-cat-holdings-report-fiscal-153200842.html Red Cat is being recognized as a major player in the drone industry. After the company's announcement of being awarded a $250 million US Army contract, the company graduated from being a small company with annual revenues under $19 million to a company likely to have 2025 revenues closer to $100 million. RCAT pulled back to under $7 from its recent high of $13, indicating a quick and healthy consolidation may be already over and the positive trend can resume.  Prospects are high for additional high value additional contracts from other US agencies (US Navy, US Marine Corps US Air Force etc) in addition to NATO countries. Wall Street research analysts will most likely begin to cover this new high growth company in a rapidly growing industry. Monday Nigh earnings call with investors will tell the tale.

ProPhase Labs $PRPH -- A year to forget ending with a capital raise for one last gap down--now at $0.65 (52 week high of $7.35). With a very low market cap of $15 million with assets and cash above that number, PRPH is one to watch going into January.

Beam Global $BEEM -- Solar-powered EV charging stations. What's not to like? From a 52 week high of $8.47 to the current $2.70, it has been a disappointing year, but the company has expanded from relying on just one product to five related products. Tax loss selling has probably been a factor in its 38% decline in the past 30 days. Watch for a rebound in January with additional news.

These are not recommendations, but are suggestion for more due diligence. $RCAT is the most timely suggestion given its announced earnings call on Monday.

I believe Comstock Mining's future is bright. Their pivot into solar panel recycling is perfectly timed as the industry grapples with the growing volume of end-of-life panels. Especially with California labelling solar panels as "Hazardous Waste" and not allowing them to go straight to landfills. They're being sent to Comstock, and Comstock gets a small profit for handling the "waste" while recycling them at near 100% efficiency and selling the materials. This, combined with their innovative waste-wood biofuel technology, positions them as a potentially invaluable company in the sustainable energy sector.

Furthermore, the consolidation of Nevada's largest mine strengthens their core business and provides a solid foundation for future growth. Their strategic investment in GenMat, a quantum-ready AI company, is particularly exciting. Given the recent breakthroughs in quantum computing, I believe GenMat's technology could revolutionize Comstock's operations and give them a significant competitive edge.

Concerns: The recent decline in the stock price is likely a reflection of the market's concern regarding the potential dilution from the Convertible Promissory Notes they've been handing out while they fund their expansion and commercialization. While this is a valid concern, I believe the long-term value proposition of Comstock's diversified business model and innovative technologies outweighs this short-term risk.

They also released a short 20 minute presentation on the potential of their company and it seems really promising. You can watch it here

TLDR; I am bullish on Comstock's prospects and believe they are well-positioned to capitalize on the growing demand for sustainable solutions and leverage cutting-edge technologies to drive significant value for shareholders.

Do you use any strategies to take a profit out of pennystocks? Reward wise can pennystocks be a nightmare. You can make large profits, but in order to do so do you need to be lucky to a certain extend and pull out at some point. Do you use any kind of strategies that have worked for you? I was for example thinking of selling half my holdings of a stock once the price doubles. This way I could get back my initial investment and keep the rest for fun. Or do you only invest long-term and don't mind any ups and downs?

Bought when it was $0.40 some months back. They did a 25-1 reverse split so that cost was recalculated to $10. Recently with all the quantum hype it rose to $29 before dropping to around $23.

The shareholders would be meeting on 18 Dec to vote on doubling the number of shares (only shareholders who bought before 29 Oct can vote). However 2/3 of shares are owned by insiders, so I assume it’s going to happen anyway. Does this mean the stock price is expected to half in the coming days? Do you plan on holding out for the long term or selling?

𝑻𝒂𝒍𝒌 𝒂𝒃𝒐𝒖𝒕 𝒚𝒐𝒖𝒓 𝒅𝒂𝒊𝒍𝒚 𝒑𝒍𝒂𝒚𝒔 𝒂𝒏𝒅 𝒄𝒐𝒎𝒎𝒆𝒏𝒕 𝒐𝒓 𝒑𝒐𝒔𝒕 𝒕𝒉𝒊𝒏𝒈𝒔 𝒉𝒆𝒓𝒆 𝒕𝒉𝒂𝒕 𝒅𝒐 𝒏𝒐𝒕 𝒘𝒂𝒓𝒓𝒂𝒏𝒕 𝒂𝒏 𝒂𝒄𝒕𝒖𝒂𝒍 𝒑𝒐𝒔𝒕.

​

𝒌𝒆𝒆𝒑 𝒊𝒕 𝒄𝒊𝒗𝒊𝒍 𝒑𝒍𝒆𝒂𝒔𝒆

Here is the response:

Important Disclaimer: I am not a financial advisor, and the following information is for educational and informational purposes only. Investing in penny stocks involves high risk, and there is no guarantee of profit. Before investing, you should conduct your own extensive research, verify all information, and consider seeking advice from a certified financial professional. Past price levels do not ensure future performance, and penny stocks can be subject to price manipulation, low liquidity, and lack of transparency.

Below is a list of 10 penny stocks that have periodically drawn attention from traders or have been discussed in investor communities as having potential catalysts. This is not an endorsement. The companies mentioned are examples based on their past market presence, and you should dive deeply into their fundamentals, SEC filings, press releases, and sector trends before making any decisions.

1. Zomedica Corp. (ZOM)

Why It’s Watched: Operates in veterinary diagnostics and pharmaceuticals. Gained attention in retail investor circles during certain market hype periods.

Due Diligence Points: Review their commercial pipeline, revenue from Truforma diagnostic platform, and recent quarterly earnings for signs of growth or a path to profitability.

2. Jaguar Health, Inc. (JAGX)

Why It’s Watched: A biotech focused on gastrointestinal products. Has experienced price volatility on news of drug developments and partnerships.

Due Diligence Points: Scrutinize drug trial results, regulatory approvals, and capital-raising activities that might dilute shareholder value.

3. Tonix Pharmaceuticals Holding Corp. (TNXP)

Why It’s Watched: A clinical-stage biopharmaceutical company researching treatments for central nervous system conditions and infectious diseases.

Due Diligence Points: Check the trial pipeline timelines, any imminent FDA milestones, and the company’s cash runway.

4. Camber Energy, Inc. (CEI)

Why It’s Watched: An oil and gas exploration and production company, often volatile due to sector swings and retail speculation.

Due Diligence Points: Monitor commodity prices, the company’s asset portfolio, and any announced mergers, acquisitions, or restructuring.

5. Ideanomics, Inc. (IDEX)

Why It’s Watched: A company operating in the electric vehicle (EV) and fintech sectors. EV enthusiasm has occasionally propelled its stock price.

Due Diligence Points: Examine revenue growth from EV-related divisions, recent acquisitions, and the adoption rate of the company’s charging and fleet solutions.

6. Remark Holdings, Inc. (MARK)

Why It’s Watched: Provides AI-driven data analytics and has grabbed attention when announcing new contracts or partnerships.

Due Diligence Points: Assess actual revenue from AI ventures, customer retention, and competition in a saturated AI/tech market.

7. Inpixon (INPX)

Why It’s Watched: Focuses on indoor data solutions, IoT, and location-based analytics.

Due Diligence Points: Look into their client base, contract wins, and how they’re differentiating from larger, better-capitalized competitors.

8. Palisade Bio, Inc. (PALI)

Why It’s Watched: A clinical-stage biotech exploring treatments for post-operative digestive issues. Early biotech investors sometimes look here for large potential upside if trials succeed.

Due Diligence Points: Study ongoing clinical trials, reported data readouts, intellectual property portfolio, and cash on hand.

9. Sorrento Therapeutics, Inc. (SRNEQ / formerly SRNE)

Why It’s Watched: Has engaged in various therapeutic areas, including oncology and COVID-related treatments. It has had periods of intense retail interest. (Note: The company has faced financial and legal challenges, currently going through bankruptcy proceedings—marked by the “Q” in the ticker—so extreme caution is advised.)

Due Diligence Points: Monitor ongoing legal proceedings, restructuring efforts, trial results, and any path to future commercialization.

10. Vinco Ventures, Inc. (BBIG)

Why It’s Watched: A holding company that has ventured into digital media and entertainment. Became a meme-stock topic on social forums.

Due Diligence Points: Clarify corporate structure, revenue sources from any new platforms or brands, and gauge whether past promotions translate into stable growth.

Next Steps in Your Research:

Check Regulatory Filings: Visit the SEC’s EDGAR database to review 10-Ks, 10-Qs, and other filings.

Analyze Financials: Ensure the company has a sustainable cash runway, minimal debt issues, and a credible management team.

Monitor News & Announcements: Watch for partnerships, FDA approvals, earnings surprises, or significant product launches.

Consider Market Sentiment: Take stock of both bullish and bearish perspectives. Forums, while risky for rumor-driven hype, can give you an idea of sentiment—but always fact-check.

Risk Management: Limit the portion of your total investment allocated to these high-risk ventures and have an exit strategy.

This list is a starting point for deeper research, not a guaranteed path to profit. Always proceed with the understanding that penny stock investing can lead to substantial losses as easily as it can yield gains.